Our findings suggest that pharmacological strategies aimed at enhancing transporter activity via LRRK2 could ameliorate pathological conditions not only in Parkinson's disease but also across a spectrum of neurodevelopmental and neurodegenerative disorders. Here, LRRK2 is linked to Parkinson disease.